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What is the appropriate management
for a patient with CIN1 on colposcopy?
■ Evidence summary
One study was found that attempted to
determine the appropriate follow-up for
women diagnosed with CIN1 on adequate
colposcopic biopsy (FIGURE). This 2-year
prospective study examined a subpopula-
tion of 1539 women from the ASCUS/LSIL
(atypical squamous cells of uncertain signif-
icance)/low-grade squamous intraepithelial
lesion) Triage Study (ALTS) to determine
the ideal follow-up strategy for women
diagnosed with CIN1 or HPV effect  on
colposcopic biopsy-obtained histology.
This study randomly assigned these women
with CIN1 or HPV effect to either HPV
testing or colposcopic examination at 6,
12, and 18 months. Every woman under-
went an exit colposcopy at 24 months. 
The study found that hr-HPV testing
12 months after the initial colposcopic
exam had the highest sensitivity for detect-
ing advanced disease (92.2%) and lowest
referral rate to repeat colposcopy (55%).
Follow-up of these patients with repeat
cytology alone at 6 and 12 months had a
lower sensitivity for detection of advanced
disease (85%) and greater referral rate to
repeat colposcopy (60%) when compared
with HPV testing at 12 months alone.
Three cytologic evaluations at 6, 12, and
18 months without HPV testing increased
sensitivity (95%), although this increase
was not statistically significant. A much
higher percentage of patients were referred
to colposcopy with this strategy.
Combining both hr-HPV testing and cytol-
ogy at 12 months did not significantly
increase the identification of advanced dis-
ease and resulted in a higher re-referral
rate to colposcopy.1–3
C L I N I C A L C O M M E N T A R Y
Base follow-up testing on patient preference, 
cost, and convenience
Patients with a colposcopic biopsy revealing mild
dysplasia (HPV effect or CIN1) need follow-up due
to the 12% risk of progression to CIN2 or CIN3
over 2 years.1 The decision to follow the patient
with either a single HPV test at 12 months or
cytologic testing at 6 and 12 months should 
be based on patient preference, cost, and 
convenience. One of the 2 follow-up strategies
should be selected and a notification system
implemented to ensure patients return at the
appropriate follow-up interval.
Of the different strategies available for managing
cervical intraepithelial neoplasia grade 1 (CIN1),
testing for high-risk subtypes of the human 
papillomavirus (hr-HPV) DNA at 12 months 
has the highest sensitivity for predicting the 
development of CIN2 or CIN3 and leads to the 
lowest rate of referral to repeat colposcopy 
(TABLE 1). If the hr-HPV DNA test result is negative
at 12 months, then the patient may return to 
routine cytology screening. If the hr-HPV DNA test
result is positive, the patient should undergo
repeat colposcopy.1,2
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Recommendations from others
American Society for Colposcopy and
Cervical Pathology consensus guidelines
for the management of women with CIN
were published in 2003. Their recom-
mendation now states that follow-up
after adequate colposcopy with a biopsy
revealing CIN1 or HPV effect may
include either repeat cervical cytology
tests at 6 and 12 months or HPV testing
at 12 months. After a negative test for
high-risk HPV types or 2 consecutive
negative cervical cytology tests, the
patient may return to annual cytologic
screening. If the HPV test is positive for
high-risk viral types or the cytology is
reported as atypical squamous cells
(ASC) or higher, the patient should
undergo repeat colposcopy.4
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FOLLOW-UP/ INTERVENTION 
AFTER DIAGNOSIS OF CIN1 SENSITIVITY FOR DETECTING REFERRAL RATE FOR REPEAT
AT COLPOSCOPY CIN1 OR HIGHER COLPOSCOPY
hr-HPV test at 12 months 92.2% 55%
hr-HPV test at 6 months 90.9% 62.4%
Cytology at 6 and 12 months 85% 60%
Cytology at 6, 12, 18 months 95% Not available
hr-HPV test and cytology 94.8% 64.1%
at 12 months
CIN1, cervical intraepithelial neoplasia grade 1; hr-HPV, high-risk subtypes of human papillomavirus. 
Source: Guido et al, Am J Obstet Gynecol 20031; Guido et al, J Lower Genital Tract Dis 2002.2
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